Innovation. Experience. Results.
Home | 
About Us | 
Contact Us | 
Glossary | 
FAQS | 

Services

Alternative Cancer Treatment

A specialized, innovative approach for difficult to treat cancers when traditional approaches are limited. A specialized, innovative treatment methodology for cancers that respond poorly to traditional approaches or have failed conventional therapy.

Understanding Drug Resistance

Unfortunately, not all tumors are receptive to traditional chemotherapeutic regimens. This is often referred to as “tumor resistance”. Even if originally effective in fighting cancer, some hereby making them ineffective. Simply put, cancers that may have been responding well to chemotherapy may start to grow again.

There are several possible reasons for this. Some of the cancerous cells may modify, become drug resistant and then grow. Another possible explanation is that a cancer cell may produce hundreds of copies of a certain gene that then produces great quantities of protein that, in effect, make the chemotherapeutic drug ineffective.

The way in which cancer cells respond can also present a challenge. For example, some cancer cells may eliminate certain drugs as fast as they enter. In some cases, cancer cells may simply stop allowing for the drug to enter, may actually repair what was meant to be destroyed by the drug, or even develop a way to render the drug ineffective.

Creating new options

The field of oncology is continually conducting research to better understand, reduce and prevent chemotherapeutic drug resistance.
Many of today’s physicians and clinicians are familiar with the idea of administering combinations of drugs, rather than single drugs, in an effort to address the issue of drug resistance.

Buckner Oncology is a pioneer in this area, leading the way in research and experience to allow physicians worldwide to better understand the what, why and how of chemotherapeutic drug combinations to enable the best arsenal of treatment optionsinthe fight against all types of cancers.

Standard chemotherapeutic treatments often have poor results,discouraging statistics often resulting in a failure rate as high as 50%. Cancer types for which this is particularly evident are:
  • Pancreatic cancer
  • Biliary tract cancers
  • Gastroesophageal cancer
  • Refractory Colon cancer
  • Sarcoma, Melanoma,
The benefit to patients is substantial – a chance to fight cancers that are stubborn and resistant to traditional therapies with a prognosis of months, not years. Many types of patients benefit from the cutting-edge therapeutic alternatives offered by Dr. Bruckner and Bruckner Oncology, including:
  • Patients who have not had success with traditional, standard therapy
  • Patientswho are unsatisfied with the reported outcomes of standard therapy
  • Patients who would not tolerate standard high dose therapy
  • Patients not eligible for clinical trials, such as the elderly over the age of 75 and those with multiple comorbidities (two or more coexisting medical conditions or diseases)
  • Patients who are not willing to participate in clinical trials
  • Patients in need of a second opinion from major academic centers
Please refer to the Testimonials section to read additional perspectives from the patient’s point of view.